Channel blocking compounds
AssigneeAgResearch Limited
InventorsJulie Dalziel, James Dunlop, Sarah Munday-Finch
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and associated methods and uses that contain lolitrem compounds containing the moiety shown in structure (I) or derivatives thereof for ion channel antagonist applications, particularly BK channel antagonist applications. Preferred compounds include lolitrem B, 31-epilolitrem B, lolitriol and lolitrem E. For lolitrem B, a particularly strong and long acting blocking effect is identified.
Claims29
A method of preventing repolarisation or hyperpolarisation of a cell, wherein the cell contains a BK channel, including the administration to the cell of at least one pharmacologically effective amount of composition containing a BK channel antagonist containing the moiety shown in structure (I):
- or derivatives thereof.
24-46. (canceled)
A composition that contains a pharmacologically effective amount of at least one BK channel antagonist compound containing the moiety shown in structure (VII):
- which includes lolitrem K=31α, 35β stereochemistry, where R=H or acetate.
A composition that contains a pharmacologically effective amount of at least one BK channel antagonist compound containing the moiety shown in structure (IX):
- which includes lolitrem M=31α, 35β stereochemistry.
A composition that contains a pharmacologically effective amount of at least one BK channel antagonist compound containing the moiety shown in structure (XII):
- which includes compounds selected from the group consisting of:
- 30-desoxylolitrem B-30α-ol=31α, 35β stereochemistry;
- 30-desoxy-31-epilolitrem B-30α-ol=31β, 35β stereochemistry.
A composition that contains a pharmacologically effective amount of at least one BK channel antagonist compound wherein the antagonist compound is structure (XIII):
- which includes 30-desoxylolitrem B-30-ene=35β stereochemistry.
Dependencies are inferred from the claim text.